These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

798 related items for PubMed ID: 16756048

  • 1. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K, Tiamkao S, Pongchaiyakul C, Pulkes T.
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [Abstract] [Full Text] [Related]

  • 2. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G, Ozekmekçi S, Apaydin H, Delil S, Erginöz E.
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [Abstract] [Full Text] [Related]

  • 3. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH, Ha JH, Cho IS, Lee MC.
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [Abstract] [Full Text] [Related]

  • 4. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S, Apaydin H, Kiliç E.
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [Abstract] [Full Text] [Related]

  • 5. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J.
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [Abstract] [Full Text] [Related]

  • 6. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 7. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM, Lees AJ, Stern GM.
    Q J Med; 1980 Apr; 49(195):283-93. PubMed ID: 7465763
    [Abstract] [Full Text] [Related]

  • 8. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 9. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
    Cubo E, González M, Aguilar A, Quintana S.
    Neurologia; 2006 Oct; 21(1):12-8. PubMed ID: 16525921
    [Abstract] [Full Text] [Related]

  • 10. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M, Miwa H, Kondo T.
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [Abstract] [Full Text] [Related]

  • 11. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 12. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J.
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [Abstract] [Full Text] [Related]

  • 13. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F, Lilliu H, Le Pen C.
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [Abstract] [Full Text] [Related]

  • 14. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
    De Reuck J, De Weweire M, Van Maele G, Santens P.
    J Neurol Sci; 2005 Apr 15; 231(1-2):35-9. PubMed ID: 15792818
    [Abstract] [Full Text] [Related]

  • 15. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
    Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG.
    Arch Neurol; 2003 Apr 15; 60(4):529-33. PubMed ID: 12707066
    [Abstract] [Full Text] [Related]

  • 16. An open label trial of pergolide in Thai patients with Parkinson's disease.
    Poungvarin N, Prayoonwiwat N, Devahasatin V, Viriyavejakul A.
    J Med Assoc Thai; 1996 Apr 15; 79(4):205-9. PubMed ID: 8708504
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Vitek JL, Bakay RA, Freeman A, Evatt M, Green J, McDonald W, Haber M, Barnhart H, Wahlay N, Triche S, Mewes K, Chockkan V, Zhang JY, DeLong MR.
    Ann Neurol; 2003 May 15; 53(5):558-69. PubMed ID: 12730989
    [Abstract] [Full Text] [Related]

  • 18. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
    Tse W.
    J Am Med Dir Assoc; 2006 Sep 15; 7(7 Suppl 2):12-7. PubMed ID: 17948614
    [Abstract] [Full Text] [Related]

  • 19. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov 15; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 20. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease.
    Wagner ML, Fedak MN, Sage JI, Mark MH.
    Ann Clin Lab Sci; 1996 Nov 15; 26(5):389-95. PubMed ID: 8879356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.